Isotopic Labeling for Metabolomics in 2025: How Advanced Tracing Technologies Are Revolutionizing Disease Research and Driving a Projected 12% CAGR Through 2030

• Executive Summary: Key Findings and Market Highlights
• Market Overview: Defining Isotopic Labeling in Metabolomics
• Current Market Size and 2025 Forecasts
• Growth Drivers: Precision Medicine, Drug Development, and Beyond
• Technological Innovations: Stable Isotope Tracers, Analytical Platforms, and Workflow Automation
• Competitive Landscape: Leading Players and Emerging Innovators
• Regulatory Environment and Standardization Efforts
• Application Deep Dive: Clinical Diagnostics, Pharmaceutical R&D, and Environmental Studies
• Regional Analysis: North America, Europe, Asia-Pacific, and Rest of World
• Market Challenges: Cost, Complexity, and Data Interpretation
• Future Outlook: Trends Shaping 2025–2030 and Market Growth Projections (12% CAGR)
• Strategic Recommendations for Stakeholders
• Sources & References

Executive Summary: Key Findings and Market Highlights

Isotopic labeling has emerged as a cornerstone technology in metabolomics, enabling precise tracking and quantification of metabolites in complex biological systems. In 2025, the global market for isotopic labeling in metabolomics continues to expand, driven by advancements in analytical instrumentation, increased adoption in pharmaceutical and clinical research, and growing interest in systems biology. The integration of stable isotopes—such as ¹³C, ¹⁵N, and ²H—into metabolic studies allows researchers to unravel metabolic pathways, fluxes, and biomarker discovery with unprecedented accuracy.

Key findings indicate that the demand for isotopically labeled compounds is particularly robust in North America and Europe, where research funding and infrastructure are well established. The Asia-Pacific region is also witnessing accelerated growth, fueled by expanding biotechnology sectors and government initiatives supporting life sciences research. Major suppliers, including Sigma-Aldrich (Merck KGaA), Cambridge Isotope Laboratories, Inc., and Thermo Fisher Scientific Inc., continue to invest in product innovation and supply chain resilience to meet rising demand.

Technological advancements in mass spectrometry and nuclear magnetic resonance (NMR) have significantly enhanced the sensitivity and throughput of isotopic labeling experiments. These improvements facilitate high-resolution metabolic flux analysis and support the development of precision medicine approaches. Furthermore, collaborations between academic institutions and industry players are accelerating the translation of metabolomics research into clinical diagnostics and therapeutic development.

Despite these positive trends, challenges remain. The high cost of labeled compounds and the technical complexity of experimental design can limit broader adoption, particularly in resource-constrained settings. Nevertheless, ongoing efforts to streamline synthesis and reduce costs are expected to broaden market accessibility.

In summary, isotopic labeling for metabolomics is poised for continued growth in 2025, underpinned by technological innovation, expanding research applications, and strategic industry partnerships. The sector’s trajectory reflects its critical role in advancing our understanding of metabolism and supporting the next generation of biomedical discoveries.

Market Overview: Defining Isotopic Labeling in Metabolomics

Isotopic labeling is a pivotal technique in metabolomics, enabling researchers to trace the fate of specific atoms through metabolic pathways by incorporating stable or radioactive isotopes into metabolites. In the context of metabolomics, isotopic labeling typically involves the use of non-radioactive, stable isotopes such as ¹³C, ¹⁵N, or ²H, which are introduced into biological systems via labeled substrates. This approach allows for the precise tracking and quantification of metabolic fluxes, pathway activities, and the dynamic turnover of metabolites in complex biological samples.

The market for isotopic labeling in metabolomics has expanded significantly, driven by advances in analytical technologies such as mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy. These technologies, offered by leading instrument manufacturers like Thermo Fisher Scientific Inc. and Bruker Corporation, have enhanced the sensitivity and resolution required to detect isotopically labeled compounds in diverse sample matrices. The integration of isotopic labeling with high-throughput metabolomics platforms has enabled researchers to unravel complex metabolic networks in fields ranging from biomedical research to agriculture and environmental science.

Key drivers of market growth include the increasing demand for systems biology approaches, the need for robust biomarker discovery, and the rising prevalence of metabolic disorders. Isotopic labeling is particularly valuable in quantitative metabolomics, where it provides internal standards for accurate metabolite quantification and helps correct for matrix effects and instrument variability. Suppliers such as Sigma-Aldrich (Merck KGaA) and Cambridge Isotope Laboratories, Inc. play a crucial role by providing a wide range of high-purity labeled compounds tailored for metabolomics research.

As the field moves toward more comprehensive and integrative omics analyses, isotopic labeling is expected to remain a cornerstone technique. Ongoing innovations in labeling strategies, sample preparation, and data analysis are likely to further expand the applications and accessibility of isotopic labeling in metabolomics, supporting both fundamental research and translational applications in 2025 and beyond.

Current Market Size and 2025 Forecasts

The global market for isotopic labeling in metabolomics has experienced steady growth, driven by increasing demand for advanced analytical techniques in life sciences, pharmaceuticals, and clinical research. Isotopic labeling, which involves incorporating stable or radioactive isotopes into molecules to trace metabolic pathways, has become a cornerstone in metabolomics for its ability to provide precise quantitative and qualitative data on cellular processes.

As of 2024, the isotopic labeling market for metabolomics is estimated to be valued at approximately USD 350–400 million. This market encompasses a range of products, including labeled compounds (such as ¹³C, ¹⁵N, and deuterium-labeled metabolites), specialized reagents, and analytical services. The primary end-users include academic research institutions, pharmaceutical companies, and biotechnology firms, all of which rely on isotopic labeling to enhance the accuracy of metabolite identification and flux analysis.

Looking ahead to 2025, the market is projected to grow at a compound annual growth rate (CAGR) of 7–9%, potentially reaching a value of USD 380–440 million. This growth is fueled by several factors:

• Rising investment in metabolomics research for drug discovery and personalized medicine.
• Technological advancements in mass spectrometry and nuclear magnetic resonance (NMR) that increase the sensitivity and throughput of isotopic labeling studies.
• Expansion of clinical and translational research initiatives, particularly in oncology and metabolic disorders, where isotopic tracing is critical for biomarker discovery.

Key players in the isotopic labeling market include Sigma-Aldrich (Merck KGaA), Cambridge Isotope Laboratories, Inc., and Thermo Fisher Scientific Inc., all of which have expanded their product portfolios to meet the growing demand for high-purity labeled compounds and custom synthesis services.

Regionally, North America and Europe dominate the market due to robust research infrastructure and funding, while Asia-Pacific is emerging as a high-growth region, supported by increasing investments in biotechnology and healthcare research.

In summary, the isotopic labeling market for metabolomics is poised for continued expansion through 2025, underpinned by technological innovation and the growing importance of metabolomics in biomedical research.

Growth Drivers: Precision Medicine, Drug Development, and Beyond

The growth of isotopic labeling in metabolomics is propelled by several key drivers, notably the rise of precision medicine, advancements in drug development, and expanding applications beyond traditional biomedical research. Isotopic labeling, which involves incorporating stable or radioactive isotopes into metabolites, enables researchers to trace metabolic pathways, quantify fluxes, and unravel complex biochemical networks with high specificity and sensitivity.

In precision medicine, isotopic labeling is instrumental for characterizing individual metabolic phenotypes and identifying biomarkers that inform tailored therapeutic strategies. By tracking labeled substrates through metabolic pathways, clinicians and researchers can detect subtle metabolic alterations associated with disease states or treatment responses. This approach supports the development of personalized interventions, as seen in initiatives led by organizations such as the National Institutes of Health and the National Cancer Institute, which leverage metabolomics to refine cancer diagnostics and monitor therapeutic efficacy.

Drug development is another major growth driver. Pharmaceutical companies utilize isotopic labeling to elucidate drug metabolism, assess pharmacokinetics, and identify potential toxic metabolites early in the development pipeline. This accelerates the drug discovery process and enhances safety profiling. For example, Pfizer Inc. and Novartis AG have integrated isotopic tracer studies into their preclinical and clinical research to optimize candidate selection and dosing regimens.

Beyond healthcare, isotopic labeling is gaining traction in fields such as agriculture, environmental science, and food safety. Researchers use labeled compounds to study nutrient cycling, trace contaminants, and authenticate food origins. Organizations like the Food and Agriculture Organization of the United Nations and the U.S. Environmental Protection Agency employ isotopic techniques to monitor ecosystem health and ensure regulatory compliance.

The continued evolution of analytical technologies, such as high-resolution mass spectrometry and nuclear magnetic resonance (NMR), further amplifies the impact of isotopic labeling. These innovations enable more precise quantification and broader metabolite coverage, driving adoption across research and industry. As a result, isotopic labeling is poised to remain a cornerstone of metabolomics, supporting advances in precision medicine, drug development, and a wide array of scientific disciplines in 2025 and beyond.

Technological Innovations: Stable Isotope Tracers, Analytical Platforms, and Workflow Automation

Technological advancements in isotopic labeling for metabolomics have significantly enhanced the precision, throughput, and interpretability of metabolic studies. Stable isotope tracers, such as ¹³C, ¹⁵N, and ²H-labeled compounds, are now routinely used to map metabolic fluxes and elucidate pathway dynamics in complex biological systems. The development and commercial availability of highly pure, position-specific labeled substrates from suppliers like Sigma-Aldrich and Cambridge Isotope Laboratories, Inc. have enabled researchers to design sophisticated tracing experiments tailored to specific metabolic questions.

Analytical platforms have also evolved, with high-resolution mass spectrometry (HRMS) and nuclear magnetic resonance (NMR) spectroscopy at the forefront. Modern HRMS instruments, such as those from Thermo Fisher Scientific Inc. and Agilent Technologies, Inc., offer unparalleled sensitivity and mass accuracy, allowing for the detection and quantification of isotopically labeled metabolites even at low abundance. These platforms support both targeted and untargeted metabolomics, facilitating comprehensive metabolic profiling and flux analysis.

Workflow automation has become increasingly important to manage the complexity and scale of isotopic labeling experiments. Automated sample preparation systems, like those provided by Tecan Group Ltd., minimize human error and increase reproducibility. Integrated software solutions, such as Bruker Corporation‘s MetaboScape and SCIEX‘s MultiQuant, streamline data acquisition, processing, and interpretation, enabling high-throughput analysis and rapid turnaround times. These tools also facilitate the integration of isotopic labeling data with other omics datasets, supporting systems-level biological insights.

Looking ahead to 2025, the convergence of advanced stable isotope tracers, state-of-the-art analytical platforms, and robust workflow automation is expected to further democratize isotopic labeling for metabolomics. This will empower a broader range of laboratories to conduct sophisticated metabolic flux analyses, accelerating discoveries in fields such as cancer metabolism, microbiome research, and personalized medicine.

Competitive Landscape: Leading Players and Emerging Innovators

The competitive landscape of isotopic labeling for metabolomics in 2025 is characterized by a dynamic interplay between established industry leaders and a growing cohort of innovative startups. Major players such as Sigma-Aldrich (Merck KGaA), Thermo Fisher Scientific Inc., and Cambridge Isotope Laboratories, Inc. continue to dominate the market with their extensive portfolios of stable isotope-labeled compounds, robust global distribution networks, and integrated solutions for metabolomics research. These companies invest heavily in R&D to expand their product offerings, improve labeling efficiency, and ensure high purity and isotopic enrichment, catering to the evolving needs of pharmaceutical, clinical, and academic researchers.

Alongside these established firms, a wave of emerging innovators is reshaping the competitive landscape. Startups and specialized companies are focusing on niche applications, such as custom synthesis of rare or complex labeled metabolites, and developing advanced labeling strategies for high-throughput and single-cell metabolomics. For example, Omixy Bio and Trace Biosciences are leveraging proprietary technologies to offer tailored isotopic labeling services and novel tracer compounds, addressing gaps in the market for precision medicine and systems biology research.

Collaborations between instrument manufacturers and labeling reagent suppliers are also shaping the sector. Partnerships between companies like Agilent Technologies, Inc. and leading isotope suppliers facilitate the development of integrated workflows, combining high-resolution mass spectrometry platforms with optimized labeled standards for quantitative metabolomics. These alliances enhance analytical accuracy and reproducibility, which are critical for biomarker discovery and metabolic flux analysis.

Furthermore, the competitive environment is influenced by regulatory compliance and quality assurance standards, with organizations such as International Organization for Standardization (ISO) setting benchmarks for product consistency and traceability. As the demand for isotopic labeling in clinical and translational research grows, companies that can demonstrate rigorous quality control and regulatory alignment are gaining a competitive edge.

In summary, the isotopic labeling for metabolomics market in 2025 is marked by the dominance of established suppliers, the agility of emerging innovators, and the strategic collaborations that drive technological advancement and market expansion.

Regulatory Environment and Standardization Efforts

The regulatory environment and standardization efforts surrounding isotopic labeling for metabolomics have become increasingly significant as the field matures and its applications expand into clinical diagnostics, pharmaceutical development, and food safety. Regulatory agencies and international organizations are working to ensure that isotopic labeling techniques are reliable, reproducible, and safe for both research and applied settings.

In the United States, the U.S. Food and Drug Administration (FDA) provides guidance on the use of stable isotopes in drug development, particularly for bioanalytical method validation and pharmacokinetic studies. The FDA emphasizes the need for validated analytical methods, including those using isotopically labeled internal standards, to ensure data integrity and comparability across laboratories.

Globally, the International Organization for Standardization (ISO) has developed standards such as ISO 17034 for reference material producers, which are relevant for suppliers of isotopically labeled compounds. These standards help guarantee the quality and traceability of labeled standards used in metabolomics workflows. Additionally, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) addresses the use of isotopic labeling in its guidelines for analytical method validation and bioanalytical studies.

Standardization efforts are also being led by scientific consortia and professional societies. The Metabolomics Society and the National Institutes of Health (NIH) have supported initiatives to develop best practices for isotopic labeling experiments, including recommendations for experimental design, data reporting, and quality control. These efforts aim to improve reproducibility and facilitate data sharing across the metabolomics community.

Despite these advances, challenges remain in harmonizing protocols and ensuring the consistent availability of high-purity labeled compounds. Ongoing collaboration between regulatory bodies, standards organizations, and the scientific community is essential to address these issues and to support the continued growth and application of isotopic labeling in metabolomics.

Application Deep Dive: Clinical Diagnostics, Pharmaceutical R&D, and Environmental Studies

Isotopic labeling has become a cornerstone technique in metabolomics, enabling precise tracking and quantification of metabolites in complex biological systems. Its applications span several critical fields, notably clinical diagnostics, pharmaceutical research and development (R&D), and environmental studies.

In clinical diagnostics, isotopic labeling is instrumental for biomarker discovery and disease mechanism elucidation. By introducing stable isotopes (such as ¹³C or ¹⁵N) into metabolic substrates, researchers can monitor metabolic fluxes and pathway alterations associated with diseases like cancer, diabetes, and metabolic syndromes. This approach enhances the sensitivity and specificity of diagnostic assays, allowing for early detection and personalized treatment strategies. For example, Mayo Clinic and other leading healthcare institutions have integrated isotopically labeled standards into their mass spectrometry-based diagnostic workflows to improve accuracy and reproducibility.

In pharmaceutical R&D, isotopic labeling is pivotal for drug metabolism and pharmacokinetics (DMPK) studies. By tracing the fate of labeled drug candidates in vitro and in vivo, researchers can identify metabolic pathways, potential toxic metabolites, and drug-drug interactions. This information is crucial for optimizing drug design and ensuring safety before clinical trials. Major pharmaceutical companies, such as Pfizer Inc. and Novartis AG, routinely employ isotopic labeling in their metabolomics platforms to accelerate lead optimization and regulatory submissions.

In environmental studies, isotopic labeling aids in tracking the fate of pollutants, nutrients, and other compounds within ecosystems. By applying labeled compounds to soil, water, or plant systems, scientists can unravel complex biogeochemical cycles and assess the impact of anthropogenic activities. Organizations like the U.S. Environmental Protection Agency utilize isotopic tracing to monitor contaminant degradation and nutrient cycling, informing remediation strategies and policy decisions.

Across these domains, advances in analytical instrumentation—particularly high-resolution mass spectrometry—have amplified the power of isotopic labeling, enabling multiplexed analyses and deeper insights into metabolic networks. As metabolomics continues to evolve, isotopic labeling will remain a vital tool for translating molecular data into actionable knowledge in health, drug development, and environmental stewardship.

Regional Analysis: North America, Europe, Asia-Pacific, and Rest of World

The global landscape for isotopic labeling in metabolomics is shaped by distinct regional trends, infrastructure, and research priorities. In North America, particularly the United States and Canada, the market is driven by robust investments in biomedical research, advanced healthcare infrastructure, and a strong presence of leading academic institutions. Organizations such as the National Institutes of Health and National Cancer Institute fund large-scale metabolomics projects, fostering demand for isotopic labeling reagents and technologies. The region also benefits from collaborations between universities and biotechnology companies, accelerating the adoption of stable isotope labeling for biomarker discovery and drug development.

In Europe, countries like Germany, the United Kingdom, and France are at the forefront, supported by initiatives from the European Commission and pan-European research infrastructures such as Euro-BioImaging. European laboratories emphasize standardization and data sharing, which has led to the development of harmonized protocols for isotopic labeling experiments. The region’s focus on personalized medicine and environmental metabolomics further stimulates the use of isotopic tracers in both clinical and ecological studies.

The Asia-Pacific region is experiencing rapid growth, propelled by increasing government funding, expanding pharmaceutical industries, and rising academic output. Countries like China, Japan, and South Korea are investing in metabolomics research through agencies such as the National Natural Science Foundation of China and Japan Science and Technology Agency. The region’s large population and growing focus on public health challenges, such as metabolic diseases, are driving demand for advanced isotopic labeling techniques and mass spectrometry platforms.

The Rest of the World—including Latin America, the Middle East, and Africa—shows emerging interest in isotopic labeling for metabolomics, though adoption is limited by infrastructure and funding constraints. However, international collaborations and capacity-building initiatives led by organizations like the International Atomic Energy Agency are gradually enhancing research capabilities in these regions. As access to analytical technologies improves, these markets are expected to contribute increasingly to global metabolomics research using isotopic labeling.

Market Challenges: Cost, Complexity, and Data Interpretation

Isotopic labeling has become a cornerstone technique in metabolomics, enabling precise tracking of metabolic pathways and fluxes. However, its broader adoption faces significant market challenges, particularly in the areas of cost, operational complexity, and data interpretation.

Cost remains a primary barrier. Isotopically labeled compounds, such as ¹³C- or ¹⁵N-labeled substrates, are often expensive to synthesize and purchase. This high cost extends to the need for specialized reagents, advanced instrumentation, and maintenance of high-resolution mass spectrometry or NMR systems. For many academic and smaller industrial laboratories, these expenses can be prohibitive, limiting access to cutting-edge isotopic labeling workflows.

Complexity is another significant challenge. Isotopic labeling experiments require meticulous experimental design, including careful selection of labeled substrates, optimization of labeling duration, and control of experimental variables. The integration of labeled compounds into biological systems must be tightly regulated to ensure meaningful results. Additionally, the operation of advanced analytical platforms, such as those provided by Thermo Fisher Scientific Inc. and Bruker Corporation, demands specialized training and expertise, further raising the barrier to entry for new users.

Data interpretation presents perhaps the most complex hurdle. Isotopic labeling generates highly intricate datasets, with overlapping isotopologue patterns and complex mass spectra. Accurate quantification and interpretation require sophisticated software tools and bioinformatics pipelines. While companies like Agilent Technologies, Inc. and Waters Corporation offer advanced data analysis solutions, the need for expert knowledge in both metabolomics and computational analysis remains high. Misinterpretation of labeling patterns can lead to erroneous biological conclusions, underscoring the importance of robust data validation and cross-disciplinary collaboration.

In summary, while isotopic labeling offers unparalleled insights into metabolic processes, its market growth is tempered by high costs, operational complexity, and the demanding nature of data interpretation. Addressing these challenges will require continued innovation in reagent production, user-friendly instrumentation, and accessible data analysis platforms, as well as expanded training initiatives from industry leaders and organizations such as the Metabolomics Society.

Future Outlook: Trends Shaping 2025–2030 and Market Growth Projections (12% CAGR)

The future of isotopic labeling for metabolomics is poised for significant growth and innovation between 2025 and 2030, with market projections indicating a robust compound annual growth rate (CAGR) of approximately 12%. This expansion is driven by several converging trends in life sciences, analytical chemistry, and clinical research.

One of the primary drivers is the increasing adoption of high-resolution mass spectrometry and nuclear magnetic resonance (NMR) technologies, which rely on isotopically labeled compounds to enhance sensitivity and accuracy in metabolite identification and quantification. As instrument manufacturers such as Thermo Fisher Scientific Inc. and Bruker Corporation continue to innovate, the integration of advanced labeling techniques with next-generation analytical platforms is expected to streamline workflows and reduce costs.

Another key trend is the growing emphasis on precision medicine and personalized healthcare. Isotopic labeling enables detailed metabolic flux analysis, which is critical for understanding disease mechanisms and therapeutic responses at the individual level. This capability is increasingly valued by pharmaceutical companies and research institutions, including F. Hoffmann-La Roche Ltd and National Institutes of Health (NIH), as they pursue biomarker discovery and drug development.

Sustainability and green chemistry are also shaping the market. The demand for environmentally friendly labeling reagents and processes is prompting suppliers such as Sigma-Aldrich (Merck KGaA) to develop novel, less hazardous isotopic compounds and scalable synthesis methods. This aligns with broader industry efforts to minimize waste and reduce the environmental footprint of laboratory operations.

Geographically, North America and Europe are expected to maintain leadership due to strong research funding and established infrastructure, while Asia-Pacific is projected to experience the fastest growth, fueled by expanding biotechnology sectors and increased government investment in life sciences.

In summary, the isotopic labeling for metabolomics market is set for dynamic expansion through 2030, propelled by technological advancements, the rise of precision medicine, sustainability initiatives, and global research investments. Stakeholders across academia, industry, and healthcare are likely to benefit from improved analytical capabilities and new application areas, reinforcing the sector’s upward trajectory.

Strategic Recommendations for Stakeholders

Strategic recommendations for stakeholders involved in isotopic labeling for metabolomics in 2025 should focus on advancing technology adoption, fostering collaboration, and ensuring regulatory compliance. As isotopic labeling techniques become increasingly integral to metabolomics research, stakeholders—including academic institutions, biotechnology companies, instrument manufacturers, and regulatory agencies—must align their strategies to maximize scientific and commercial benefits.

• Invest in Advanced Analytical Platforms: Stakeholders should prioritize investment in high-resolution mass spectrometry and nuclear magnetic resonance (NMR) systems optimized for isotopic labeling studies. Collaborating with leading instrument manufacturers such as Thermo Fisher Scientific Inc. and Bruker Corporation can facilitate access to cutting-edge technologies and technical support.
• Standardize Protocols and Data Sharing: Establishing standardized protocols for isotopic labeling experiments and data analysis is crucial for reproducibility and cross-laboratory comparisons. Stakeholders should engage with organizations like the Metabolomics Society to contribute to and adopt best practice guidelines.
• Enhance Training and Education: Academic and industry stakeholders should develop comprehensive training programs to build expertise in isotopic labeling methodologies and data interpretation. Partnerships with universities and professional societies can help disseminate knowledge and foster a skilled workforce.
• Promote Interdisciplinary Collaboration: Encouraging collaboration between chemists, biologists, data scientists, and clinicians will accelerate innovation and application of isotopic labeling in diverse fields such as drug development, clinical diagnostics, and systems biology.
• Address Regulatory and Ethical Considerations: Stakeholders must stay informed about evolving regulatory requirements for isotopically labeled compounds, especially in clinical and pharmaceutical contexts. Engaging with regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency will ensure compliance and facilitate market access.
• Support Open-Access Resources: Contributing to and utilizing open-access metabolomics databases and software tools, such as those supported by the European Bioinformatics Institute, can enhance data transparency and accelerate scientific discovery.

By implementing these strategic recommendations, stakeholders can drive innovation, improve research quality, and expand the impact of isotopic labeling in metabolomics for 2025 and beyond.

Sources & References

• Thermo Fisher Scientific Inc.
• Bruker Corporation
• National Institutes of Health
• National Cancer Institute
• Novartis AG
• Food and Agriculture Organization of the United Nations
• Tecan Group Ltd.
• SCIEX
• Cambridge Isotope Laboratories, Inc.
• International Organization for Standardization (ISO)
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)
• Mayo Clinic
• European Commission
• Euro-BioImaging
• Japan Science and Technology Agency
• International Atomic Energy Agency
• F. Hoffmann-La Roche Ltd
• European Medicines Agency
• European Bioinformatics Institute